PATHOLOGICAL UPTAKE WITH 18-FLUOROCHOLINE VERSUS 99mTc-MIBI IN THE LOCATION OF THE PARATHYROID GLANDS IN HYPERPARATHYROIDISM. SYSTEMATIC REVIEW AND META-ANALYSIS

Captación patológica con 18-Fluorocolina frente a 99mTc-MIBI en la localización de las glándulas paratiroides en el hiperparatiroidismo. Revisión sistemática y metanálisis

José Luis PARDAL REFOYO1, Pilar TAMAYO ALONSO2, Sofía FERREIRA CENDÓN1, Esther MARTÍN GÓMEZ2

1University Hospital of Salamanca, Salamanca. 2University Hospital of Salamanca, Salamanca. Biomedical Research Institute (IBSAL). Nuclear Medicine

Correspondence: jlpardal@usal.es

SUMMARY: Introduction: The location of the pathological parathyroid glands in hyperparathyroidism is usually carried out by means of 99mTc-sestamibi scintigraphy, which increases its precision by adding the ultrasound examination. The non-localization of the parathyroid glands increases the difficulties for surgical removal. To increase the detection of pathological glands, other radioactive tracers are used, such as methionine, fluorocholine or 18F-flurpiridaz.

Objective: To establish if PET / CT with 18-Fluorocholine in patients with hyperparathyroidism increases the number of uptakes compared to the 99mTc-sestamibi scan.

Method: Systematic review and meta-analysis. Two subgroups were analyzed. Subgroup 1: trials comparing both techniques as an initial exploration.
selected (596 PET / CT with 18-Fluorocholine vs. 535 scintigraphy with 99mTc-sestamibi). Meta-analysis was performed following the random effects model and the odds ratio was calculated. Subgroup 2: studies that include 18-Fluorocholine as a rescue examination in patients with a previous negative study with a 99mTc-sestamibi scan. 17 articles including 412 examinations with 359 patients in which there was at least one uptake were selected. Meta-analysis of the prevalence of the number of patients in whom there was at least one uptake was performed using the random effects model.

Results: Subgroup 1: The number of patients in which at least one uptake occurs is significantly higher with the 18-Fluorocholine examinations (OR 4.264, 95% CI 2.400-7.577). The prevalence of uptake with 18-Fluorocholine is 0.91 [0.86, 0.95] and with sestamibi 0.68 [0.56, 0.80]. Subgroup 2: the prevalence of uptake among patients with previous negative MIBI studies was 0.90 [0.87, 0.94]. The probability of detection of both techniques in this group reaches 0.98. Publication bias in the meta-analyzes is low.

Discussion: 18-Fluorocholine protocols provide higher precision, clearer images, with faster acquisition as well as being readily available for most PET / CT centers.

Conclusion: The PET / CT study with 18-Fluorocholine can be recommended as a study for the location of pathological parathyroid glands after studies with negative MIBI.

KEYWORDS: Hyperparathyroidism; parathyroid; sestamibi scintigraphy; choline PET; fluorocholine

RESUMEN: Introducción: La localización de las glándulas paratiroides patológicas en el hiperparatiroidismo usualmente se realiza mediante gammagrafía con 99mTc-sestamibi que incrementa su precisión al añadir la exploración ecográfica. La no localización de las glándulas paratiroides incrementa las dificultades para la extirpación quirúrgica. Para incrementar la detección de glándulas patológicas se utilizan otros trazadores radiactivos como la metionina, la fluorocolina o el 18F-flurpiridaz.

Objetivo: Establecer si el PET/TC con 18-Fluorocolina en pacientes con hiperparatiroidismo incrementa el número captaciones comparada con la gammagrafía con 99mTc-sestamibi.

Método: Revisión sistemática y metanálisis. Se analizaron dos subgrupos. Subgrupo 1: ensayos que comparan ambas técnicas como exploración inicial. Se seleccionaron 13 estudios que incluyen 1131 exploraciones (596 PET/TC con 18-Fluorocolina vs. 535 gammagrafía con 99mTc-sestamibi). Se realizó metanálisis siguiendo el modelo de efectos aleatorios y se calculó la odds ratio. Subgrupo 2: estudios que incluyen la 18-Fluorocolina como exploración de rescate en pacientes con estudio previo negativo con gammagrafía con 99mTc-sestamibi. Se seleccionaron 17 artículos que incluyen 412 exploraciones con 359 pacientes en los que al menos hubo una captación. Se realizó metanálisis de la prevalencia del número de pacientes en los que hubo al menos una captación aplicando el modelo de efectos aleatorios.

Resultados: Subgrupo 1: El número de pacientes en los que se presenta al menos una captación es significativamente superior con las exploraciones con 18-Fluorocolina (OR 4.264, IC 95% 2.400-7.577). La prevalencia de captaciones con 18-Fluorocolina es de 0.91 [0.86, 0.95] y con sestamibi de 0.68 [0.56, 0.80]. Subgrupo 2: la prevalencia de captaciones entre pacientes con estudios MIBI negativos previos fue de 0.90 [0.87, 0.94]. La probabilidad de detección de ambas técnicas en este grupo llega al 0.98 El sesgo de publicación en los metanálisis es bajo.

Discusión: Los protocolos con 18-Fluorocolina proporcionan mayor precisión, imágenes más claras, con una adquisición más rápida además de estar fácilmente disponible para la mayoría de los centros PET / CT.

Conclusión: El estudio PET/TC con 18-Fluorocolina puede recomendarse como estudio para la localización de las glándulas paratiroides patológicas tras estudios con MIBI negativos.

PALABRAS CLAVE: hiperparatiroidismo; paratiroides; PET colina; gammagrafía MIBI; fluorocolina
INTRODUCTION

The location of the pathological parathyroid glands in hyperparathyroidism is usually performed by SPECT/TC scan with 99mTc-sestamibi (MIBI) which increases their accuracy when associating ultrasound scanning. The non-location of the parathyroid glands increases difficulties for surgical removal. Other radioactive tracers such as methionine or fluorocholine are used to increase the detection of pathological glands [1–8].

The usefulness of PET/TC with 18-Fluorocholine (CH) was established after incidental findings of pathological parathyroid in males tracking for prostate cancer. In 2012 Mapelli et al., in 2013 Quak et al. and, in 2014 Hodolic et al. described cases of incidental uptake in parathyroids in explorations with F-18-fluorocholine in males with prostate cancer and proposed it as a study in case of negative MIBI [9–11]. Subsequent studies have confirmed this indication [12–14].

The accuracy of nuclear scans in the location of pathological parathyroid glands in hyperparathyroidism has been widely published and debated in the literature and the absence of localization poses a greater difficulty in surgical treatment so research is continued to establish a diagnostic strategy that offers the highest number of true positives and fewer false negatives.

The objective of this review is to know whether PET/TC with 18-Fluorocholine in patients with hyperparathyroidism increases the number of catches compared to the scan with 99mTc-MIBI by bibliographic review.

METHOD

The following research PICO question was asked: In patients with primary hyperparathyroidism [patient] the location of the pathological glands [intervention] by PET/TC with 18-Fluorocholine (CH) versus SPECT/TC with 99mTc-MIBI (MIBI) [comparison] does it offer more detections with suspected pathology? [outcome].


Inclusion criteria: studies including patients with hyperparathyroidism undergoing scan with 99mTc-Sesta-MIBI (MIBI) and 18F-choline PET/CT (CH) as first scan (subgroup 1) and patients with study 99mTc-Sesta-MIBI (MIBI) negative in the first scan to be performed second rescue scan with 18F-choline PET/CT (CH) in which there was at least a significant scan uptake (subgroup 2). Articles indicating the number of patients scanned and the number of patients in whom there was at least a positive uptake in the neck or mediastinum and those in which there was no uptake or this nor was conclusive evaluated with SUVmax measurement (maximum standardized absorption value).

Exclusion criteria: clinical cases, conferences, conferences with published data or parathyroid cancer series exclusively.

Each article obtained the total number of patients with scans performed and calculated the prevalence of patients in which there was at least one uptake (positive uptake) or there was no uptake, or this was doubtful (negative uptake).

Two subgroups were analyzed:

Subgroup 1: essays comparing both techniques (CH vs. MIBI) as an initial scan.

Meta-analysis of dicotomical models was performed following the random effects model, the odds ratio and the publication bias were calculated.

Subgroup 2: studies that include CH as a rescue scan in patients with prior negative study with MIBI scan.

Meta-analysis of the prevalence of the number of patients in which there was at least one uptake was performed using the random effects model and the publication bias was evaluated.
Pathological uptake with 18-Fluorocholine versus 99mTc-MIBI in the location of the parathyroid glands in hyperparathyroidism. Systematic review and meta-analysis

Pardal-Refoyo et al.

Figure 1. Bibliographical search and literature selection strategies.
Pathological uptake with 18-Fluorocholine versus 99mTc-MIBI in the location of the parathyroid glands in hyperparathyroidism. Systematic review and meta-analysis

Pardal-Refoyo et al.


The statistical program JAMOVI 1.2.22 (The jamovi project 2020, https://www.jamovi.org) was used.

STUDY LIMITATIONS

- Only patients where at least one scan uptake was detected.
- The number of uptakes per patient was not evaluated.
- Patients with primary hyperparathyroidism are included but in some cases the diagnosis is not clear.
- Correlation of catchments with surgical findings was not sought to assess the accuracy of the tests.
- It is assumed that the scan uptake increases the probability of surgical location.

RESULTS

SUBGROUP 1

13 studies including 1131 scans (596 PET/TC with 18-Fluorocholine vs. 535 SPECT/TC scan with 99mTc-sestamibi) [14,17–28] were selected. See Table 1.

Table 1. Subgroup 1: MIBI vs CH as the first scan. Results table.

<table>
<thead>
<tr>
<th>study name</th>
<th>CH PET/TC</th>
<th>CAPTURES</th>
<th>NO CAPTURE</th>
<th>99mTc-sestamibi SPECT/CT</th>
<th>CAPTURES</th>
<th>NO CAPTURE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thansser 2017 [17]</td>
<td>54</td>
<td>52</td>
<td>2</td>
<td>54</td>
<td>42</td>
<td>12</td>
</tr>
<tr>
<td>Orevi 2014 [21]</td>
<td>40</td>
<td>37</td>
<td>3</td>
<td>40</td>
<td>33</td>
<td>7</td>
</tr>
<tr>
<td>Beheshti 2018 [22]</td>
<td>82</td>
<td>76</td>
<td>6</td>
<td>82</td>
<td>50</td>
<td>32</td>
</tr>
<tr>
<td>Araz 2018 [24]</td>
<td>35</td>
<td>30</td>
<td>5</td>
<td>35</td>
<td>28</td>
<td>7</td>
</tr>
<tr>
<td>Bossert 2019 [25]</td>
<td>34</td>
<td>24</td>
<td>10</td>
<td>34</td>
<td>5</td>
<td>29</td>
</tr>
<tr>
<td>Araz 2018 2 [23]</td>
<td>43</td>
<td>42</td>
<td>1</td>
<td>43</td>
<td>35</td>
<td>8</td>
</tr>
<tr>
<td>Imamovic 2016 [26]</td>
<td>41</td>
<td>39</td>
<td>2</td>
<td>41</td>
<td>27</td>
<td>14</td>
</tr>
<tr>
<td>Hocevar 2017 [27]</td>
<td>151</td>
<td>126</td>
<td>25</td>
<td>90</td>
<td>74</td>
<td>16</td>
</tr>
<tr>
<td>Kluijfhout 2016 [28]</td>
<td>44</td>
<td>34</td>
<td>10</td>
<td>44</td>
<td>14</td>
<td>30</td>
</tr>
<tr>
<td>Michaud 2015 [14]</td>
<td>17</td>
<td>15</td>
<td>2</td>
<td>17</td>
<td>15</td>
<td>2</td>
</tr>
<tr>
<td>Lezaic 2014 [20]</td>
<td>24</td>
<td>24</td>
<td>0</td>
<td>24</td>
<td>20</td>
<td>4</td>
</tr>
<tr>
<td>Michaud 2014 [18]</td>
<td>12</td>
<td>11</td>
<td>1</td>
<td>12</td>
<td>7</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>596</td>
<td>526</td>
<td>70</td>
<td>535</td>
<td>364</td>
<td>171</td>
</tr>
</tbody>
</table>

The number of patients with at least one uptake is significantly higher with 18-Fluorocholine scans (OR 4.264, CI 95% 2.400-7.577). The prevalence of uptakes with 18-Fluorocholine is 0.91 [0.86, 0.95] and with MIBI of 0.68 [0.56, 0.80]. See Figure 2 and Table 2.
Pathological uptake with 18-Fluorocholine versus 99mTc-MIBI in the location of the parathyroid glands in hyperparathyroidism. Systematic review and meta-analysis

Pardal-Refoyo et al.

Figure 2. Subgroup 1: MIBI vs CH as the first scan. Forest plot.

Table 2. Statistical heterogeneity.

<table>
<thead>
<tr>
<th></th>
<th>Estimate</th>
<th>se</th>
<th>z</th>
<th>p</th>
<th>CI Lower Bound</th>
<th>CI Upper Bound</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intercept</td>
<td>1.45</td>
<td>0.293</td>
<td>4.95</td>
<td>&lt;.001</td>
<td>0.875</td>
<td>2.025</td>
</tr>
</tbody>
</table>

Note. Tau² Estimator: Restricted Maximum-Likelihood

Heterogeneity Statistics

<table>
<thead>
<tr>
<th>Tau</th>
<th>Tau² (SE= 0.4357)</th>
<th>I²</th>
<th>H²</th>
<th>R²</th>
<th>df</th>
<th>Q</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.742</td>
<td>0.5498</td>
<td>55.35%</td>
<td>2.239</td>
<td>.</td>
<td>12.000</td>
<td>29.741</td>
<td>0.003</td>
</tr>
</tbody>
</table>

Back-Transform Log Odds Ratio to Odds Ratio

<table>
<thead>
<tr>
<th>Odds Ratio</th>
<th>CI Lower Bound</th>
<th>CI Upper Bound</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.264</td>
<td>2.400</td>
<td>7.577</td>
</tr>
</tbody>
</table>

Robust Paired Samples-T-Test

<table>
<thead>
<tr>
<th>CAPTA_CH</th>
<th>CAPTA_MIBI</th>
<th>t</th>
<th>df</th>
<th>p</th>
<th>Mean difference</th>
<th>SE</th>
<th>95% Confidence Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>3.49</td>
<td>8.00</td>
<td>0.008</td>
<td>7.78</td>
<td>2.23</td>
<td>Lower: 12.922, Upper: 0.317</td>
</tr>
<tr>
<td>NOCAPTA_CH</td>
<td>NOCAPTA_MIBI</td>
<td>−2.60</td>
<td>8.00</td>
<td>0.032</td>
<td>−7.67</td>
<td>2.95</td>
<td>Lower: −14.48, Upper: −0.858</td>
</tr>
</tbody>
</table>
The publication bias is moderate (I²=55.35%). See Figure 3.

Figure 3. Subgroup 1: MIBI vs CH as the first scan. Funnel plot and publication bias.
Pathological uptake with 18-Fluorocholine versus 99mTc-MIBI in the location of the parathyroid glands in hyperparathyroidism. Systematic review and meta-analysis

Pardal-Refoyo et al.

Subgroup 2

17 articles including 412 scans were selected with at least 359 patients in which there was at least one uptake [17,21,23,29–41]. See Table 3.

The prevalence of uptakes among patients with prior negative MIBI studies was 0.90 [0.87, 0.94]. The probability of detection of both techniques in this group reaches 0.98. See Figure 4 and Table 4.

Table 3. Subgroup 2: CH as a rescue scan in negative MIBI. Results table.

<table>
<thead>
<tr>
<th>Study name</th>
<th>N</th>
<th>CAPTURES</th>
<th>NO CAPTURE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Piccardo 2019 [35]</td>
<td>44</td>
<td>32</td>
<td>12</td>
</tr>
<tr>
<td>Thansser 2017 [17]</td>
<td>11</td>
<td>11</td>
<td>0</td>
</tr>
<tr>
<td>Orevi 2014 [21]</td>
<td>7</td>
<td>7</td>
<td>0</td>
</tr>
<tr>
<td>Zajickova 2018 [36]</td>
<td>13</td>
<td>12</td>
<td>1</td>
</tr>
<tr>
<td>Kluijfhout 2017 [37]</td>
<td>10</td>
<td>9</td>
<td>1</td>
</tr>
<tr>
<td>Quak 2018 [38]</td>
<td>25</td>
<td>22</td>
<td>3</td>
</tr>
<tr>
<td>Morales 2018 [39]</td>
<td>49</td>
<td>42</td>
<td>7</td>
</tr>
<tr>
<td>Bera 2018 [40]</td>
<td>29</td>
<td>26</td>
<td>3</td>
</tr>
<tr>
<td>Amadou 2019 [41]</td>
<td>29</td>
<td>28</td>
<td>1</td>
</tr>
<tr>
<td>Liu 2019 [29]</td>
<td>87</td>
<td>70</td>
<td>17</td>
</tr>
<tr>
<td>Christakis 2019 [30]</td>
<td>12</td>
<td>12</td>
<td>0</td>
</tr>
<tr>
<td>Collaud 2019 [31]</td>
<td>7</td>
<td>6</td>
<td>1</td>
</tr>
<tr>
<td>Grimaldi 2018 [32]</td>
<td>27</td>
<td>24</td>
<td>3</td>
</tr>
<tr>
<td>Huber 2018 [33]</td>
<td>26</td>
<td>25</td>
<td>1</td>
</tr>
<tr>
<td>Kluijfhout 2015 [37]</td>
<td>5</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>Treglia 2016 [34]</td>
<td>23</td>
<td>21</td>
<td>2</td>
</tr>
<tr>
<td>Araz 2018 2 [23]</td>
<td>8</td>
<td>8</td>
<td>0</td>
</tr>
</tbody>
</table>

412 359 53

Figure 4. Subgroup 2: CH as a rescue scan in negative MIBI. Forest plot.
Pathological uptake with 18-Fluorocholine versus 99mTc-MIBI in the location of the parathyroid glands in hyperparathyroidism. Systematic review and meta-analysis

Pardal-Refoyo et al.

Table 4. Statistical heterogeneity.

<table>
<thead>
<tr>
<th>Heterogeneity Statistics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tau</td>
</tr>
<tr>
<td>0.042</td>
</tr>
</tbody>
</table>

Note. Tau^2 Estimator: Restricted Maximum-Likelihood

The publication bias in meta-analysis is low (I^2-34.5%). See Figure 5.

Figure 5. Subgroup 2: CH as a rescue scan in negative MIBI. Funnel plot and publishing bias. (Continued)
DISCUSSION

Currently, the definitive treatment of hyperparathyroidism is the surgical removal of the gland or pathological glands. Negative localization studies make surgical treatment difficult.

In both the selected articles in our meta-analysis and in previous meta-analysis, CH localization studies have shown greater ability to locate pathological glands [34,42–45] than MIBI or methionine [46–48] in both first exploration and rescue scan [31,49].

The probability of uptake with CH is above 0.9 on both first scans and scans performed after negative MIBI study (in these cases the combination of both techniques reaches a prevalence of uptake of 0.97). See Figure 6.

The CH localization study using PET/TC offers advantages such as higher number of uptakes (both the number of patients with at least one uptake and the higher number of multiple adenoma or hyperplasia captures [20], shorter imaging time [14] and exposure of patients with less radiation than the SPECT/CT hybrid image with Tc-99m-sestaMIBI [50].

As disadvantages is the difficulty in distinguishing catches in thyroid, nodes, thymus or muscle (false positives) [50] and logistical problems [14].

CH scan may be indicated both as an initial scan and in patients with prior negative MIBI study.
CONCLUSIONS

1. Ultrasound-associated SPECT/TC-MIBI scan is currently the scan of choice for the location of pathological parathyroid glands prior to surgery.
2. PET-Choline scan increases the number of patients with at least one uptake on both the first scan and on scans with initial negative MIBI studies.
3. Currently PET-Choline scan seems an option to locate pathological glands in patients with negative initial scan.

REFERENCES

Pathological uptake with 18-Fluorocholine versus 99mTc-MIBI in the location of the parathyroid glands in hyperparathyroidism. Systematic review and meta-analysis
Pardal-Refoyo et al.


Pathological uptake with 18-Fluorocholine versus 99mTc-MIBI in the location of the parathyroid glands in hyperparathyroidism. Systematic review and meta-analysis

Pardal-Refoyo et al.


Pathological uptake with 18-Fluorocholine versus 99mTc-MIBI in the location of the parathyroid glands in hyperparathyroidism. Systematic review and meta-analysis

Pardal-Refoyo et al.


49. Broos WAM, Van Der Zant FM, Knol RJ, Wondergem M. Choline PET/CT in parathyroid imaging:
Pathological uptake with 18-Fluorocholine versus 99mTc-MIBI in the location of the parathyroid glands in hyperparathyroidism. Systematic review and meta-analysis

Pardal-Refoyo et al.
